



## SYSTEM SPECIFICATIONS




### iStent inject stents

Made of titanium and coated with heparin, iStent inject is the smallest medical device known to be implanted in the human body



### Insertion tube with window

Optimises visualisation of stents during implantation




### Two preloaded stents in the iStent inject system

The iStent inject system is composed of two stents in a single-use, sterile injector



# TRANSFORMING MIGS IN MORE WAYS THAN ONE.



- **Optimised Outflow:** Two multi-directional stents designed to restore natural outflow
- **Clinically Proven:** Significant IOP reduction across a wide range of clinical studies<sup>1,2</sup>
- **Procedural Elegance:** Predictability and precision to meet the needs of your practice
- **Proven Safety:** Safety profile similar to cataract surgery alone<sup>1</sup>

All with the exceptional customer support you've come to expect from Glaukos.



## Ordering Information

Order Number: G2-M-IS-AS  
Tel.: 02 8882 4900  
Fax: 02 8882 4999  
E-Mail: [Glaukos\\_CS@Linfox.com](mailto:Glaukos_CS@Linfox.com)  
[glaukos.com](http://glaukos.com)



GLAUKOS AUSTRALIA  
Suite 109/12 Corporate Drive • Heatherton VIC • 3202  
tel 03 9551 2220 • [Glaukos.com](http://Glaukos.com)

**GLAUKOS**<sup>®</sup>  
Transforming Glaucoma Therapy

**INDICATION FOR USE.** The iStent *inject* Trabecular Micro-Bypass System (Model G2-M-IS-AS) is intended to reduce intraocular pressure in adult patients diagnosed with mild to moderate primary open-angle glaucoma (POAG) currently treated with ocular hypotensive medication. The device can be implanted with or without cataract surgery. **CONTRAINDICATIONS.** The device is contraindicated for use in eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations, and in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. **WARNINGS.** This device has not been studied in patients with uveitic glaucoma. Patients should be informed that placement of the stents, without concomitant cataract surgery in phakic patients, can enhance the formation or progression of cataract. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. iStent *inject* is MR-Conditional, meaning that the device is safe for use in a specified MRI environment under specified conditions; please see labelling for details. Physician training is required prior to use and consists of 3 parts: webinar, Didactic session with Glaukos surgical representative and observation of surgical cases by Glaukos representative until implantation proficiency is demonstrated. Do not re-use the stent(s) or injector. **ADVERSE EVENTS.** Postoperative adverse events include but are not limited to: corneal complications including edema, opacification and decompensation, cataract formation (in phakic patients), posterior capsule opacification, stent obstruction, intraocular inflammation (non-preexisting), BCVA loss and IOP increase requiring management with oral or intravenous medications or surgical intervention. Please refer to Directions for Use for additional adverse event information. **CAUTION:** Please reference the Directions For Use labelling for a complete list of contraindications, warnings and adverse events.

**REFERENCES:** 1. iStent *inject*® Trabecular Micro-Bypass System: Directions for Use, Part # 45-0176. 2. Hengerer FH. Personal experience with second-generation trabecular micro-bypass stents in combination with cataract surgery in patients with glaucoma: 3-year follow-up. ASCRS 2018 Presentation.

© 2018 Glaukos Corporation. Glaukos and iStent *inject* are registered trademarks of Glaukos Corporation. Australian Sponsor – RQsolutions Pty Ltd.  
PM-AU-0038